Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML
Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML
Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.
Dasatinib Misses Survival End Points in Core-Binding Factor AML
Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.